Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 239S · 10 late239 trades$59.22M
Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 25 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $1.38M 9,212 sh | Feb 4, 2026 |
| 25 | Novack Jeffrey AdamSecretary and General Counsel |  CDNACareDx, Inc.Open-market sale | SELL | $91K 4,441 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $41K 200 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $8,162 40 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Fang AndyDirector | DASHDoorDash, Inc. Open-market sale · 10b5-1 plan | SELL | $16K 80 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Stat Lauren Elaina FriedmanDirector | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $60K 400 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 23 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $4,723 100 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 22 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $374K 2,525 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 22 | Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $308K 1,334 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $558K 2,415 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Fesko JohnPRESIDENT, CHIEF BUS. OFFICER | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $272K 1,179 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Smith Michael AlexanderChief Legal Officer |  INSMINSMED IncOpen-market sale | SELL | $100K 640 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 22 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $942K 6,310 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 21 | Mat IshbiaDirector, President and CEO, 10% Owner |  UWMCUWM Holdings CorpOpen-market sale · 10b5-1 plan | SELL | $3.20M 632.9K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 21 | Mat IshbiaDirector, President and CEO, 10% Owner | UWMCUWM Holdings Corp Open-market sale · 10b5-1 plan | SELL | $3.30M 632.9K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 20 | Schwartz Richard ToddDirector, Chief Executive Officer |  RSIRush Street Interactive, Inc.Open-market sale · 10b5-1 plan | SELL | $4.35M 247.1K sh | Feb 4, 2026 traded Feb 4, 2026 |
| 20 | Malenka Robert C.Director |  MPLTMapLight Therapeutics, Inc.Open-market sale | SELL | $127K 7,039 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $106K 720 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $187K 4,064 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moore Alexander D.Director | PLTRPalantir Technologies Inc. Open-market sale · 10b5-1 plan | SELL | $186K 1,233 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 19 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $378K 1,639 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 18 | Howse CurtisSee remarks |  SYFSynchrony FinancialOpen-market sale · 10b5-1 plan | SELL | $3.80M 52.6K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malabre Richard CSVP, Chief Accounting Officer |  AKBAAkebia Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $50K 36.1K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 17 | Malenka Robert C.Director | MPLTMapLight Therapeutics, Inc. Open-market sale | SELL | $18 1 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $197K 850 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Stetz MattiasChief Operating Officer | RSIRush Street Interactive, Inc. Open-market sale · 10b5-1 plan | SELL | $353K 20.0K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $133K 576 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $140K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 16 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $202K 878 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Wampler Kira SchererDirector |  DOCSDoximity, Inc.Open-market sale · 10b5-1 plan | SELL | $75K 2,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $18K 80 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS | NTRANatera, Inc. Open-market sale · 10b5-1 plan | SELL | $3,744 16 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 13 | Sharma ManishChief Strategy & Services Ofcr | ACNAccenture plc Open-market sale · 10b5-1 plan | SELL | $25K 98 sh | Feb 4, 2026 traded Feb 3, 2026 |
| 13 | Schafer JoshuaCCO |  ZVRAZEVRA THERAPEUTICS, INC.Open-market sale · 10b5-1 plan | SELL | $97K 10.5K sh | Feb 4, 2026 traded Feb 3, 2026 |
| 12 | Bachrodt AmySVP, Finance | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $34K 736 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 11 | Bernstein HaroldPresident, R&D & CMO | MAZEMaze Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $27K 600 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 11 | Holleran KevinDirector, President and CEO |  HAYWHayward Holdings, Inc.Open-market sale · 10b5-1 plan | SELL | $841K 52.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Malabre Richard CSVP, Chief Accounting Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $19K 13.4K sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Alpern Paul LVP and General Counsel |  AIPArteris, Inc.Open-market sale · 10b5-1 plan | SELL | $77K 5,000 sh | Feb 4, 2026 traded Feb 2, 2026 |
| 10 | Rucci Carolyn M.SVP, Chief Legal Officer | AKBAAkebia Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $23K 16.8K sh | Feb 4, 2026 traded Feb 2, 2026 |
TSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
MTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
ADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K